Francis Joseph Carr

This inventor holds 15 USPTO granted patents and 4 published patent applications, plus 11 CIPO patents and 7 EPO patents, primarily in Immunotherapy Research. Top assignees: Redwood Bioscience, Inc., Biogen Ma Inc., Biovation Limited. Active years: 2005-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Francis Joseph Carr. Retrieved from https://idiyas.com/inventor/francis-joseph-carr-5mhe97td

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 4)

% Patents Active = 60.0

CIPO Patents = 11 (Patent Applications = 12)

EPO Patents = 7 (Patent Applications = 3)

Average Co-Inventor Count = 3.3

ph-index = 5

Forward Citations = 98(Granted Patents)

Company Filing History:

3 out of 19

Redwood Bioscience, Inc.

Nkt Therapeutics Inc.

Proclara Biosciences, Inc.

Years Active: 2005-2024

Loading Chart...

Areas of Expertise:

Antibody

CD22

Dementia Treatment

Polypeptide

Immune Therapy

iNKT

Streptokinase

Bacteriophage

Immunogenicity

Alpha V Beta 6

Protein Screening

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12116409 - Antibody specific for CD22 and methods of use thereof (2024-10-15),

2. 11485792 - Antibodies, uses thereof and conjugates thereof (2022-11-01),

3. 10259871 - Antibody specific for CD22 and methods of use thereof (2019-04-16),

4. 10035860 - Anti-alpha V beta 6 antibodies and uses thereof (2018-07-31),

5. 10035859 - Anti-alpha V beta 6 antibodies and uses thereof (2018-07-31),

6. 9988444 - Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity (2018-06-05),

7. 9932402 - Humanized antibodies to iNKT (2018-04-03),

8. 9879076 - Methods and compositions with immune therapy for treatment of dementia (2018-01-30),

9. 9677055 - [object Object] (2017-06-13),

10. 9371517 - [object Object] (2016-06-21),

11. 9181343 - Antibody specific for CD22 and methods of use thereof (2015-11-10),

12. 8932586 - [object Object] (2015-01-13),

13. 7465572 - De-immunized streptokinase (2008-12-16),

14. 7125689 - Method for rendering streptokinase less immunogenic to a human (2006-10-24),

15. 6927025 - Methods for protein screening (2005-08-09),

Title: The Innovative Journey of Francis Joseph Carr

Introduction

Francis Joseph Carr, an esteemed inventor from Aberdeen, GB, has made significant contributions to the field of biomedicine. With a remarkable portfolio of 15 patents, Carr has focused his research on the development of antibodies and their applications in diagnosing and treating various diseases, including cancer. His innovative spirit and dedication to science have marked him as a prominent figure in his field.

Latest Patents

Carr's latest patents highlight his expertise in antibody technology. One notable invention is an "Antibody specific for CD22 and methods of use thereof," which provides antibodies that target an epitope present on CD22. These antibodies hold promise for various therapeutic, diagnostic, and monitoring applications.

Additionally, he has developed patents encompassing "Antibodies, uses thereof and conjugates thereof." This invention details a specific antibody that binds to PSMA, including a heavy chain variable domain with precise amino acid sequences. The implications of this work are vast, particularly in the treatment and diagnosis of cancers, especially prostate cancer.

Career Highlights

Throughout his career, Carr has been affiliated with innovative companies that have allowed him to excel in his research. He has worked with Redwood Bioscience, Inc. and Biovation Limited, gaining valuable experience and contributing to advancements in biotechnology. His dedication to research and development continues to drive his inventive endeavors.

Collaborations

Collaboration has been a key aspect of Carr's career. He has worked alongside talented individuals, including Timothy David Jones and Robert George Edward Holgate, fostering a dynamic environment for innovation. These collaborations have undoubtedly enriched his work and facilitated the advancement of significant biomedical discoveries.

Conclusion

Francis Joseph Carr's journey as an inventor showcases his commitment to advancing biomedical technology through innovative antibody research. With his impressive number of patents and notable collaborations, Carr continues to make impactful contributions to the healthcare sector, particularly in the fight against cancer. His work stands as a testament to the power of innovation and collaboration in advancing scientific knowledge.

Profile summary based on public USPTO records.